Idelalisib

Idelalisib
	Idelalisib structure
Clinical data
Pronunciation	/aɪˈdɛləlɪsɪb/; eye-DEL-ə-li-sib
Trade names	Zydelig
Other names	GS-1101, CAL-101
AHFS/Drugs.com	Monograph
MedlinePlus	a614040
Pregnancy; category	AU: D;
Routes of; administration	Oral
ATC code	L01EM01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	>84%
Metabolism	Aldehyde oxidase (~70%), CYP3A4 (~30%); UGT1A4 (minor)
Metabolites	GS-563117 (inactive in vitro)
Onset of action	Tmax = 1.5 hours
Elimination half-life	8.2 hours
Excretion	Feces (78%), urine (14%)
Identifiers
	IUPAC name 5-Fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone;
CAS Number	870281-82-6;
PubChem CID	11625818;
DrugBank	DB09054;
ChemSpider	9800565;
UNII	YG57I8T5M0;
KEGG	D10560;
ChEBI	CHEBI:82701 ;
ChEMBL	ChEMBL2216870;
CompTox Dashboard (EPA)	DTXSID701007266 ;
ECHA InfoCard	100.235.089
Chemical and physical data
Formula	C22H18FN7O
Molar mass	415.432 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](Nc1ncnc2nc[nH]c12)c4nc3cccc(F)c3c(=O)n4c5ccccc5;
	InChI InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1; Key:IFSDAJWBUCMOAH-HNNXBMFYSA-N;

Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase. It was developed by Gilead Sciences. It is taken orally (swallowed by mouth).

Clinical data
Idelalisib structure
Pronunciation	/aɪˈdɛləlɪsɪb/ eye-DEL-ə-li-sib
Trade names	Zydelig
Other names	GS-1101, CAL-101
AHFS/Drugs.com	Monograph
MedlinePlus	a614040
Pregnancy category	AU: D
Routes of administration	Oral
ATC code	L01EM01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	>84%
Metabolism	Aldehyde oxidase (~70%), CYP3A4 (~30%); UGT1A4 (minor)
Metabolites	GS-563117 (inactive in vitro)
Onset of action	T_max = 1.5 hours
Elimination half-life	8.2 hours
Excretion	Feces (78%), urine (14%)
Identifiers
IUPAC name 5-Fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone
CAS Number	870281-82-6
PubChem CID	11625818
DrugBank	DB09054
ChemSpider	9800565
UNII	YG57I8T5M0
KEGG	D10560
ChEBI	CHEBI:82701^Y
ChEMBL	ChEMBL2216870
CompTox Dashboard (EPA)	DTXSID701007266
ECHA InfoCard	100.235.089
Chemical and physical data
Formula	C₂₂H₁₈FN₇O
Molar mass	415.432 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC[C@H](Nc1ncnc2nc[nH]c12)c4nc3cccc(F)c3c(=O)n4c5ccccc5
InChI InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1 Key:IFSDAJWBUCMOAH-HNNXBMFYSA-N